CAR-T

Phase 3Cell therapy

HHebei Senlang Biotechnology Inc., Ltd.

CAR-T is one of 328 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

327

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Connective Tissue DiseaseActive, not recruiting

Brain GliomaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Plasma Cell LeukemiaActive, not recruiting

Colorectal CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Multiple MyelomaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Connective Tissue DiseasePreclinical

Active, not recruiting

Brain GliomaPhase 1

Active, not recruiting

Autoimmune DiseasePreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Plasma Cell LeukemiaPhase 1

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Phase 3

3 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Maintenance Therapy

NCT06695013

Q3 2027

Recruiting

Lymphoma

NCT07236203

Q4 2027

Phase 2Not yet recruiting

Maintenance Therapy

NCT06646666

Phase 1Recruiting

Treatment

NCT07143929

Phase 2Recruiting

Multiple Myeloma, Refractory

NCT07689058

Q1 2028

Phase 1Not yet recruiting

Multiple Myeloma

NCT06913192

Clinical

Trials by Indication[1]

Lymphoma3 trials

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Recruiting·FFudan University··NCT07236203·80 enrolled

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

Recruiting·HHong Kong Children's Hospital·N/A·NCT06866873·18 enrolled

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05322330·20 enrolled

Treatment3 trials

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 1·NCT07338357·10 enrolled

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

Recruiting·PPeking University People's Hospital·Phase 1·NCT07143929·18 enrolled

CAR-T Cells in the Treatment of Malignant Hematological Tumors

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT05619861·20 enrolled

Maintenance Therapy2 trials

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06646666·35 enrolled

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

Recruiting·RRuijin Hospital·Phase 2·NCT06695013·144 enrolled

CAR-T2 trials

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

Not yet recruiting·XXuzhou Medical University·Phase 2·NCT06963866·60 enrolled

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Recruiting·PPeking University People's Hospital·Phase 3·NCT07441291·70 enrolled

Multiple Myeloma2 trials

Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma

Not yet recruiting·XXuzhou Medical University·Phase 1·NCT06913192·50 enrolled

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT07169500·50 enrolled

22 more indications

Mantle Cell Lymphoma1 trial

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06504199·39 enrolled

R/R B-NHL1 trial

CAR-T for R/R B-NHL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT03196830·10 enrolled

Brain Glioma1 trial

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Recruiting·JJIANG LONGWEI·Phase 1·NCT06828341·3 enrolled

Acute Myeloid Leukemia1 trial

Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting·XXuzhou Medical University·Phase 1/2·NCT07370064·20 enrolled

Colorectal Cancer1 trial

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Recruiting·GGuangzhou Bio-gene Technology Co., Ltd·N/A·NCT07152210·20 enrolled

Connective Tissue Disease1 trial

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Recruiting·GGuangzhou Bio-gene Technology Co., Ltd·N/A·NCT07152223·20 enrolled

Plasma Cell Leukemia1 trial

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting·CChunrui Li·Phase 1·NCT05219721·18 enrolled

Metastatic Colorectal Cancer1 trial

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Unknown status·TThe Third Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT05248048·9 enrolled

Renal Cell Carcinoma1 trial

Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy

Not yet recruiting·WWei Guan·Phase 1·NCT07113977·30 enrolled

Infusion1 trial

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 1/2·NCT04846439·20 enrolled

Myeloma1 trial

CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?

Not yet recruiting·XXuzhou Medical University·Phase 2·NCT07070934·60 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT07223021·130 enrolled

Safety and Efficacy1 trial

Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors

Recruiting·GGuangzhou Bio-gene Technology Co., Ltd·N/A·NCT07152236·20 enrolled

Malignancy1 trial

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

Unknown status·KKai Lin Xu; Jun Nian Zheng·Phase 1/2·NCT02782351·50 enrolled

Hematologic Malignancies1 trial

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Recruiting·—·Phase 1·NCT06758713·60 enrolled

Newly Diagnosed1 trial

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible

Not yet recruiting·XXuzhou Medical University·N/A·NCT07070960·35 enrolled

Autoimmune Disease1 trial

A Study of CAR-T Cells Targeting Autoimmune Diseases

Not yet recruiting·—·N/A·NCT06661811·12 enrolled

Relapsed or Refractory1 trial

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Recruiting·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT06136364·9 enrolled

Malignant Tumors1 trial

CAR-T for r/r Malignant Tumors in Children

Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1·NCT04691349·10 enrolled

Transplantation1 trial

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04796441·20 enrolled

Multiple Myeloma, Refractory1 trial

Pilot, Open-Label, Single-Arm Study of Autologous BCMA-Directed CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma in Pakistan

Recruiting·DDr. Zaineb Akram·Phase 2·NCT07689058·10 enrolled

Large B-cell Lymphoma1 trial

A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy

Recruiting·AAbramson Cancer Center at Penn Medicine·Phase 1·NCT07478848·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Senlang Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: HHebei Senlang Biotechnology Inc., Ltd.

CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Lymphoma3 trials

Treatment3 trials

Maintenance Therapy2 trials

CAR-T2 trials

Multiple Myeloma2 trials

Mantle Cell Lymphoma1 trial

R/R B-NHL1 trial

Brain Glioma1 trial

Acute Myeloid Leukemia1 trial

Colorectal Cancer1 trial

Connective Tissue Disease1 trial

Plasma Cell Leukemia1 trial

Metastatic Colorectal Cancer1 trial

Renal Cell Carcinoma1 trial

Infusion1 trial

Myeloma1 trial

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy1 trial

Malignancy1 trial

Hematologic Malignancies1 trial

Newly Diagnosed1 trial

Autoimmune Disease1 trial

Relapsed or Refractory1 trial

Malignant Tumors1 trial

Transplantation1 trial

Multiple Myeloma, Refractory1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News